Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18–70 years old
- Your cancer was confirmed by pathology (tissue examination) and you had complete surgical removal
- Your cancer type is pancreatic, bile duct, liver, or stomach cancer
- Your doctor expects you to live at least 12 more months
- Your blood counts and organ function (kidneys, liver) must be in a safe range
- You cannot have active cancer spread or other recent serious health problems like heart attack or stroke
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new treatment called XH001 combined with standard immunotherapy and chemotherapy for people whose pancreatic cancer has been surgically removed. The goal is to see if this combination helps prevent the cancer from coming back.
This trial tests a two-part treatment: an injection called XH001 plus a custom vaccine that trains your immune cells to attack tumors. It's for people with advanced stomach or bowel cancer that hasn't responded to at least two prior treatments.
This trial tests a new tumor vaccine (XH001) combined with standard chemotherapy after surgery for pancreatic cancer. The goal is to lower the chance of the cancer coming back.
This trial tests two new drugs, HX009 and IN10018, with or without standard chemotherapy, for people with advanced solid tumors that haven't responded to treatment or have no standard options. It aims to see if this combination can help shrink or control the cancer.
This early trial tests whether JCXH-212 alone, or with toripalimab (an immunotherapy drug), is safe and tolerable in people with advanced solid cancers. It also looks at whether treatment can help by targeting tumor “neoantigens” found in your tumor tissue.
This trial tests an experimental cell therapy (HS-IT101) for people with advanced solid tumors that have not responded to standard treatments. It uses immune cells from your own tumor to fight cancer, and researchers want to see if it is safe and effective.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.